Skip to content

On this page

Egrifta WR

tesamorelin

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Egrifta WR

Proper name

tesamorelin

Licence type

351(a)

BLA number

022505

Applicant

Theratechnologies Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
11.6MG	For Injection	Subcutaneous	Multi-Dose Vial	Rx	March 25, 2025

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity